Results 161 to 170 of about 10,718 (215)

Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion. [PDF]

open access: yesNat Commun
Roulstone V   +30 more
europepmc   +1 more source

Transplant International: Looking Back at 2025, Looking Forward to 2026. [PDF]

open access: yesTranspl Int
Berney T   +9 more
europepmc   +1 more source

Correction: Baradad-Jurjo et al. Measurement of Melanocytic Choroidal Lesions: Ultrasound Versus Ultrawide-Field Fundus Imaging System. <i>Cancers</i> 2025, <i>17</i>, 642. [PDF]

open access: yesCancers (Basel)
Baradad-Jurjo MC   +10 more
europepmc   +1 more source

Successful Endoscopic Ethanol Injection and Clipping Treatment of Ruptured Duodenal Varices. [PDF]

open access: yesTurk J Gastroenterol
Abayli B   +5 more
europepmc   +1 more source

Preoperative middle meningeal artery embolization is associated with reduced reoperation rates in chronic subdural hematoma. [PDF]

open access: yesInterv Neuroradiol
Salim HA   +13 more
europepmc   +1 more source

Challenges of small hospitals in Japan during the COVID-19 pandemic. [PDF]

open access: yesAntimicrob Steward Healthc Epidemiol
Agata C, Do DA, Yazawa T, Gu Y.
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Previous Papanicolaou and Hybrid Capture 2 human papillomavirus testing results of 5699 women with histologically diagnosed cervical intraepithelial neoplasia 2/3

Journal of the American Society of Cytopathology, 2019
Cervical cancer remains an important public health problem in Chinese women owing to the lack of a national screening program. The aim of the present study was to evaluate human papillomavirus (HPV) and Papanicolaou (Pap) test results preceding the histologic diagnosis of cervical intraepithelial neoplasia 2/3 (CIN2/3) in China's largest College of ...
Baowen Zheng, Chengquan Zhao
exaly   +3 more sources

Abstract 5699: Tegavivint directly targets TBL1 to inhibit b-catenin nuclear oncogenic activity

Cancer Research
Abstract Tegavivint (BC2059) is a first-in-class small molecule that has demonstrated clinical activity in multiple cancer types including HCC and NSCLC. Tegavivint binds to TBL1 resulting in inhibition of Wnt/β-catenin oncogenic activity.
Aundrietta Duncan   +5 more
exaly   +2 more sources

Home - About - Disclaimer - Privacy